Physics World names UC, Cincinnati Children's study among top 10 Breakthroughs of 2022
FLASH radiation therapy trial recognized for significance in advancing scientific progress
Physics World recognized the University of Cincinnati and Cincinnati Children's Hospital Medical Center's FAST-01 study as one of its top 10 Breakthroughs of the Year for 2022.
Photo courtesy of Physics World.
The first-in-human trial tested FLASH radiation treatment (FLASH RT), a method that delivers therapeutic doses of radiation in a fraction of a second. FLASH RT was shown to be as safe and appeared to be as effective as conventional radiation without causing unexpected side effects in the study in a small number of people with bone cancer.
Findings of the FAST-01 trial were published in JAMA Oncology and presented Oct. 23 at the American Society for Radiation Oncology (ASTRO) annual meeting.
The Physics World top 10 Breakthroughs of the Year list spans areas including quantum and medical physics, astronomy and condensed matter. The Breakthroughs are selected by a panel of Physics World editors who reviewed research published on the site in 2022 based on the following criteria:
- Significant advance in knowledge or understanding
- Importance of work for scientific progress and/or development of real-world applications
- Of general interest to Physics World readers
The FAST-01 trial was led by Emily Daugherty, MD, assistant professor of clinical radiation oncology at the University of Cincinnati Cancer Center; John Breneman, MD, professor of radiation oncology at the Cancer Center and. medical director of the Cincinnati Children's/UC Medical Center Proton Therapy Center; John P. Perentesis, MD, research director of the Proton Therapy Center; and Anthony Mascia, PhD, chief physicist for the center.
“Our study shows FLASH radiotherapy with protons is a practical modality to reduce pain,” Daugherty said. “It deserves further exploration because of its potential to decrease the side effects associated with conventional radiation treatments.”
FLASH radiotherapy delivers radiation at dose rates that are more than 300 times higher than those used in conventional radiation treatments. This induces a phenomenon known as the FLASH effect, which reduces the harm that may occur to normal tissue surrounding a tumor during conventional radiation therapy, while still killing the cancer cells at the tumor site.
“Because FLASH radiotherapy, which is given at ultrahigh dose rates, appears to cause less normal tissue injury, it offers the possibility of delivering larger doses of radiation which could result in higher cure rates for patients with resistant tumors without increasing side effects of treatment,” Breneman said.
The overall Physics World Breakthrough of the Year will be revealed on Wednesday, Dec. 14.
Read the Physics World top 10 Breakthroughs of the Year list.
Read the Physics World coverage of the FAST-01 trial.
Featured photo at top of Dr. Daugherty with a patient. Photo/Colleen Kelley/UC Marketing + Brand.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.